Renalytix Plc (LON:RENX – Get Free Report)’s share price dropped 3.4% on Wednesday . The company traded as low as GBX 11 ($0.14) and last traded at GBX 11.11 ($0.14). Approximately 181,677 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 344,406 shares. The stock had previously closed at GBX 11.50 ($0.14).
Renalytix Price Performance
The firm’s 50-day moving average is GBX 9.71 and its two-hundred day moving average is GBX 10.29. The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53. The stock has a market cap of £19.08 million, a P/E ratio of -47.92 and a beta of 2.10.
Insider Activity
In other Renalytix news, insider James Renwick McCullough acquired 53,300 shares of Renalytix stock in a transaction on Thursday, December 5th. The shares were purchased at an average cost of GBX 8 ($0.10) per share, with a total value of £4,264 ($5,324.01). 35.74% of the stock is currently owned by insiders.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S.
Further Reading
- Five stocks we like better than Renalytix
- Manufacturing Stocks Investing
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How Technical Indicators Can Help You Find Oversold Stocks
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
